

**APREA THERAPEUTICS, INC.**  
**3805 Old Easton Road**  
**Doylestown, PA 18902**

April 25, 2024

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Chris Edwards

Re: Aprea Therapeutics, Inc.  
Registration Statement on Form S-3  
File No. 333-278485  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the “**Registrant**”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278485), so that it may become effective at 4:30 p.m. Eastern Time on April 29, 2024, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Fahd Riaz, Esq. of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement.

Very truly yours,

**APREA THERAPEUTICS, INC.**

By: /s/ Oren Gilad

Name: Oren Gilad

Title: Chief Executive Officer

cc: Patrick O’Malley, Esq., *DLA Piper LLP (US)*  
Dylan Caplan, Esq., *DLA Piper LLP (US)*

---